Astrazeneca Share News (AZN)

LONDON MARKET CLOSE: Stocks Slip As Focus Moves To Fed's Yellen

Britain's FTSE retreats as pharma stocks fall

* FTSE 100 down 0.3 pct * Pharma stocks down after Clinton's EpiPen comments * Glencore leads miners lower * CRH rises after results (ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemar

Thursday newspaper share tips: WPP and Astrazeneca

(ShareCast News) - The mood in advertising giant WPP should be pretty good, opines Financial Times' Lex column, which, in something of a novelty, cites Martin Sorrell's healthy tan. Something to do with enhanced moods due to the sun and serotonin release, the column wheezed. It noted that, as was t

LONDON MARKET MIDDAY: Stocks Down As Clinton Remarks Hit Pharma Sector

Shire, AstraZeneca and Hikma hit by Hillary Clinton's pharma-bashing

(ShareCast News) - Hikma Pharmaceuticals, Shire and AstraZeneca were among FTSE-listed drug companies slipping lower on Thursday morning, following comments from US presidential favourite Hillary Clinton on pharmaceutical pricing that hit peers across the Atlantic overnight. Clinton joined senators

Britain's FTSE retreats as pharma stocks fall

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 down 0.8 pct * Pharma stocks down after Clinton's EpiPen comments * Glencore leads miners lower * CRH rises afte

UPDATE 1-Pfizer to buy antibiotics business from AstraZeneca

* British firm sells non-core antibiotics unit to Pfizer * Says deal fits strategy of focusing on cancer and other areas * Pfizer will pay $550 mln on completion and $175 mln in 2019 * Will also pay sales-related payments and royalties (Adds details, shares) LONDON, Aug

AstraZeneca sells antibiotics business to Pfizer for £1.2bn

(ShareCast News) - AstraZeneca has agreed to sell its antibiotics business to US giant Pfizer for staged payments amounting to $1.6bn (£1.2bn) plus recurring, double-digit royalties on future sales. The FTSE 100 group said the sale would reinforces its focus on developing medicines in its three main

AstraZeneca to sell antibiotics business to Pfizer

LONDON, Aug 24 (Reuters) - Pharmaceutical company AstraZeneca said it had agreed to sell its small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5 billion. The portfolio includes approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which

FTSE 100 movers: Housebuilders lead equities higher

(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index. Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 J

AstraZeneca completes licensing agreement with LEO Pharma

(ShareCast News) - AstraZeneca has completed a licensing agreement with LEO Pharma, a specialist in dermatology care, for the global licence to monoclonal antibody tralokinumab in skin diseases. Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of $115m for the exclusive, gl

AstraZeneca wins UK cost approval for longer use of heart drug

LONDON, Aug 12 (Reuters) - Long term use of AstraZeneca's blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain's healthcare cost watchdog NICE said on Friday. Ticagrelor 60 mg -- sold in Britain as Brilique for just und

Thursday broker round-up

(ShareCast News) - Astrazeneca: Berenberg reiterates buy with a target price of 5600p. Legal & General: RBC maintains outperform with a 300p target. Lloyds: JP Morgan reiterates neutral with a 62p target. Centamin: RBC stays at speculative risk with a 190p target. Staffline: Berenberg reiterates

BROKER RATINGS SUMMARY: Barclays Cuts Travis Perkins To Underweight

Astrazeneca ups interest in Moderna Therapeutics with $140m investment

(ShareCast News) - Astrazeneca has upped its equity interest in Moderna Therapeutics with a $140m investment as part of the biotechnology company's preferred-stock financing. Astrazeneca had already purchased a stake in Massachusetts-based Moderna to develop messenger RNA medicines for the potential